Active — Not RecruitingPhase 2

Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial

China120 participantsStarted 2025-08-15

Plain-language summary

This clinical trial aims to compare the effectiveness and safety of two treatment options for patients with high-risk upper tract urothelial carcinoma (UTUC). One group will receive neoadjuvant chemotherapy with gemcitabine and cisplatin followed by surgery (radical nephroureterectomy), while the other group will undergo surgery without chemotherapy. The primary goal is to assess the pathological response to treatment, focusing on how much the tumor shrinks before surgery. The trial will also evaluate the safety of the treatments, overall survival, and recurrence-free survival. This study will help determine whether adding chemotherapy before surgery improves outcomes for patients with high-risk UTUC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed high-risk upper tract urothelial carcinoma (UTUC).
✓. Clinically non-metastatic UTUC (N≤1, M0) based on imaging (CT/MRI).
✓. Planned for radical nephroureterectomy (RNU).
✓. ECOG performance status of 0 or 1.
✓. Sufficient renal function (GFR ≥45 mL/min) and able to tolerate chemotherapy with cisplatin.
✓. Age ≥18 years.
✓. Informed consent signed.

Exclusion criteria

✕. Imaging shows ≥N2 disease or metastatic disease (M1).
✕. History of invasive or lymph node-positive UTUC or invasive disease in the contralateral upper tract in the last 2 years.
✕. Single kidney or contraindication to cisplatin.
✕

What they're measuring

Pathological Response Rate

Timeframe: 6 weeks after surgery

Trial details

NCT IDNCT07492225

SponsorChanghai Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-15

View on ClinicalTrials.gov More Neoadjuvant Therapy trials